IJCRR

IJCRR - 7(12), June, 2015

Pages: 60-63

CLINICAL PRESENTATION AND MANAGEMENT OF 100 CONSECUTIVE CASES OF THYROID
ASSOCIATED OPHTHALMOPATHY SEEN IN THE OUT- PATIENT DEPARTMENT OF A REGIONAL INSTITUTE OF OPHTHALMOLOGY

Author: Garima Agrawal

Category: Healthcare

[Download PDF]

Abstract:

Introduction: Thyroid associated ophthalmopathy is an autoimmune disorder. It is a life -long disease with systemic and ocular manifestations. Early diagnosis and appropriate management of this disorder are essential.
Aim: Clinical presentation and management of 100 consecutive cases of Thyroid associated ophthalmopathy seen in the outpatient department of a regional institute of ophthalmology.
Material and Methods: All patients of Thyroid associated ophthalmopathyseen in our institute were subjected to a complete clinical work up, ultrasonography B scan, computed tomographic scan, triiodothronine, thyroxine and thyroid stimulating hormone assays. Treatment of thyroid dysfunction and thyroid ophthalmopathy were given as per protocol.
Observation and Results: Age of patients ranged from 17-63 years. The female:male ratio was 1.7:1. Distribution of thyroid dysfunction was hyperthyroidism (96%), hypothyroidism(3%) and euthyroid(1%). Majority of patients had mild (68%) and /or quiescent disease(77%). Eyelid retraction was the most common presentation (88%). Other presentations were exophthalmos( 63%), extraocular myopathy(37%), soft tissue inflammation (23%) and optic neuropathy (12%). Thyroid dysfunction was treated with anti thyroid drugs(100%), thyroidectomy(12%), radioactive iodine(1%). Thyroid ophthalmopathy was treated with
supportive therapy(100%), glucocorticoids(32%), ocular surgery(27%), orbital radiotherapy (1%), cyclosporine(1%).
Conclusion: We present the clinical manifestations and management of Thyroid associated ophthalmopathy patients at a regionalinstitute of ophthalmology. A larger percent of patients required glucocorticoids reflecting the referral of moderate-severe and/or active patients to our tertiary care centre.

Keywords: Thyroid associated ophthalmopathy, Clinical presentation, Management

References:

1. Bartalena Luigi, Tanda Maria Laura. Grave’s Ophthalmopathy. N Engl J Med 2009;360:994-1001.

2. Bartalena L, Baldeschi L,Dickinson A et al.Consensus statement of the European Group on Grave’s Orbitopathy (EUGOGO) on management of Graves orbitopathy. Eur J Endocrinol 2008;158:273-285.

3. Bartalena L, Baldeschi L, Dickinson A et al. Consensus statement of the European Group on Grave’s Orbitopathy(EUGOGO) on management of Graves orbitopathy. Thyroid 2008;18:333-346.

4. Zang S, Ponto KA, Kahaly GJ. Clinical review:I ntravenous glucocorticoids for Graves Orbitopathy:efficacy and morbidity. J ClinEndocrinol Metab 2011;96(2): 320-32.

5. Bartley GB, Fatourechi V, Kadrmas EF, Jacobsen SJ, Ilstrup DM, Garrity JA, Gorman CA. Clinical features of Graves’ ophthalmopathy in an incidence cohort. Am J Ophthalmol 1996 Mar;121(3):284-90.

6. Bartley GB. The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc. 1994;92:477-588.

7. Bartley GB, Fatourechi V, Kadrmas EF, Jacobsen SJ, Ilstrup DM, Garrity JA, Gorman CA. Chronology of Graves’ ophthalmopathy in an incidence cohort. Am J Ophthalmol. 1996 Apr;121(4):426-34.

8. Jankauskiene J, Imbrasiene D. Investigations of ocular changes, extraocular muscle thickness, and eye movements in Graves’ ophthalmopathy. JhnMedicina (Kaunas). 2006;42(11):900-3.

9. Bartley GB1, Fatourechi V, Kadrmas EF, Jacobsen SJ, Ilstrup DM, Garrity JA, Gorman CA. The treatment of Graves’ ophthalmopathy in an incidence cohort. Am J Ophthalmol. 1996 Feb;121(2):200-6.

10. Marcocci C1, Bartalena L, Bogazzi F, Panicucci M, Pinchera A. Studies on the occurrence of ophthalmopathy in Graves’ disease. ActaEndocrinol (Copenh). 1989 Apr;120(4):473.